ADAMs and ADAMTs Selective Synthetic Inhibitors

Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications

Volumn , Issue , 2009, Pages 591-645

  Rossello, Armando ^a   Nuti, Elisa ^a   Maresca, Alfonso ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

ADAMs and ADAMTs selective synthetic inhibitors; Phosphonamido based TACE inhibitors; TACE novel nonhydroxamate inhibitors

Indexed keywords

EID: 77949834395     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470508169.ch26     Document Type: Chapter

References (162)

1. Fowlkes, J. L.;Winkler, M. K. Survey exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev. 2002, 13, 277-287.
2. Rocks, N.; Paulissen, G.; El Hour, M.; Quesada, F.; Crahay, C.; Gueders, M.; Foidart, J. M.; Noel, A.; Cataldo, D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008, 90, 369-379.
3. Mochizuki, S.; Okada,Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98, 621-628.
4. Rowan, A. D.; Litherland, G. J.; Hui, W.; Milner, J. M. Metalloproteinases as potential therapeutic targets in arthritis treatment. Expert Opin. Ther. Targets. 2008, 12, 1-18.
5. Yang, P. K.; Baker, A.; Hagg, T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog. Neurobiol. 2006, 79, 73-94.
6. Lovering, F.; Zhang, Y. Therapeutic potential of TACE inhibitors in stroke. Curr. Drug Targets. 2005, 4, 161-168.
7. Moss, M. L.; White, J. M.; Andrews, L.; Andrews, R. C. TACE and otherADAMproteases as targets for drug discovery. Drug Discov. Today. 2001, 6, 417-426.
8. Stocker, W.; Bode, W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr. Opin. Struct. Biol. 1995, 5, 383-390.
9. Boldt, H. B.; Overgaard, M. T.; Laurensen, L. S.;Weyer, K.; Sottrup-Jensen, L.; Oxvig, C. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): classification as a metzincin. Biochem. J. 2001, 358, 359-367.
10. Blobel, C. P. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell. 1997, 90, 589-592.
11. Zhang, X. P.; Kamata, T.; Yokoyama, K.; Puzon-McLaughlin, W.; Takada, Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alpha v beta 3. J. Biol. Chem. 1998, 273, 7345-7350.
12. Loechel, F.; Gilpin, B. J.; Engvall, E.; Albrechtsen, R.; Wewer, U. M. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J. Biol. Chem. 1998, 273, 16993-16997.
13. Black, R. A.; White, J. M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 1998, 10, 654-659.
14. Eto, K.; Huet, C.; Tarui, T.; Kupriyanov, S.; Liu, H. Z.; Puzon-McLaughlin, W.; Zhang, X. P.; Sheppard, D.; Engvall, E.; Takada, Y. Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9 beta 1: implications for sperm-egg binding and other cell interactions. J. Biol. Chem. 2002, 277, 17804-17810.
15. Reiss, K.; Ludwig, A.; Saftig, P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther. 2006, 111, 985-1006.
16. Takeda, S.; Igarashi, T.; Mori, H.; Araki, S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J. 2006, 25, 2388-2396.
17. Huovila, A. P.; Almeida, E. A.; White, J. M. ADAMs and cell fusion. Curr. Opin. Cell Biol. 1996, 8, 692-699.
18. Stone, A. L.; Kroeger, M.; Sang, Q. X. Structure-function analysis of the ADAMfamily of disintegrin-like and metalloproteinase-containing proteins. J. Protein Chem. 1999, 18, 447-465.
19. Seals, D. F.; Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17, 7-30.
20. Apte, S. S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int. J. Biochem. Cell Biol. 2004, 36, 981-985.
21. Cal, S.; Obaya, A. J.; Llamazares, M.; Garabaya, C.; Quesada, V.; Lopez-Otin, C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002, 83, 49-62.
22. Porter, S.; Clark, I. M.; Kevorkian, L.; Edwards, D. R. The ADAMTS metalloproteinases. Biochem. J. 2005, 386, 15-27.
23. Kaushal, G. P.; Shah, S. V. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J. Clin. Invest. 2000, 105, 1335-1337.
24. Tang, B. L.; Hong, W. ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. 1999, 445, 223-225.
25. Amour, A.; Knight, C. G.; Webster, A.; Slocombe, P. M.; Stephens, P. E.; Knäuper, V.; Docherty, A. J.; Murphy, G. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000, 473, 275-279.
26. Kashiwagi, M.; Tortorella, M.; Nagase, H.; Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAMTS4) and aggrecanase 2 (ADAMTS5). J. Biol. Chem.. 2001, 276, 12501-12504.
27. Murphy, G.; Knäuper, V.; Lee, M. H.; Amour, A.;Worley, J. R.; Hutton, M.; Atkinson, S.; Rapti, M.; Williamson, R. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem. Soc. Symp. 2003, 70, 65-80.
28. Nagase, H.; Brew, K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem. Soc. Symp. 2003, 70, 201-212.
29. Amour, A.; Knight, C. G.; English, W. R.; Webster, A.; Slocombe, P. M.; Knäuper, V.; Docherty, A. J.; Becherer, J. D.; Blobel, C. P.; Murphy, G. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002, 524, 154-158.
30. Wayne, G. J.; Deng, S. J.; Amour, A.; Borman, S.; Matico, R.; Carter, H. L.; Murphy, G. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is regulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J. Biol. Chem. 2007, 282, 20991-20998.
31. Küper, C.;Bartels, H.; Fraek, M. L.; Beck, F. X.; Neuhofer,W. Ectodomain shedding of pro-TGF-a is required for COX-2 induction and cell survival in renal medullary cells exposed to osmotic stress. Am. J. Physiol. Cell Physiol.. 2007, 293, C1971-C1982.
32. Auerbach, I. D.; Vinters, H. V. Effects of anoxia and hypoxia on amyloid precursor protein processing in cerebral microvascular smooth muscle cells. J. Neuropathol. Exp. Neurol. 2006, 65, 610-620.
33. Kenny, P. A. TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation. 2007, 75, 800-808.
34. Zhou, B. B.; Peyton, M.; He, B.; Liu, C.; Girard, L.; Caudler, E.; Lo, Y.; Baribaud, F.; Mikami, I.; Reguart, N.;Yang, G.; Li, Y.;Yao, W.;Vaddi, K.; Gazdar, A. F.; Friedman, S. M.; Jablons, D. M.; Newton, R. C.; Fridman, J. S.; Minna, J. D.; Schrle, P. A. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006, 10, 39-50.
35. Fridman, J. S.; Caulder, E.; Hansbury, M.; Liu, X.; Yang, G.;Wang, Q.; Lo, Y.; Zhou, B. B.; Pan, M.; Thomas, S. M.; Grandis, J. R.; Zhuo, J.; Yao, W.; Newton, R. C.; Friedman, S. M.; Scherle, P. A.; Vaddi, K. Selective inhibition of ADAM metalloproteases as a novel approach formodulating ErbB pathways in cancer.Clin.Cancer Res. 2007, 13, 1892-1902.
36. Rosso, O.; Piazza, T.; Bongarzone, I.; Rossello, A.; Mezzanzanica, D.; Canevari, S.; Orengo, A. M.; Puppo, A.; Ferrini, S.; Fabbi, M. The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol. Cancer Res. 2007, 5, 1246-1253.
37. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.;Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature. 1997, 385, 729-732.
38. Moss, M. L.; Jin, S. L.; Milla, M. E.; Bickett, D.M.; Burkhart, W.; Carter, H. L.; Chen, W. J.; Clay, W. C.; Didsbury, J. R.; Hassler, D.; Hoffman, C. R.; Kost, T. A.; Lambert, M. H.; Leesnitzer, M. A.; McCauley, P.; McGeehan, G.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L. K.; Schoenen, F.; Seaton, T.; Su, J.L.; Becherer, J. D. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-a. Nature. 1997, 385, 733-736.
39. Rosendahl, M. S.; Ko, S. C.; Long, D. L.; Brewer, M. T.; Rosenzweig, B.; Hedl, E.; Anderson, L.; Pyle, S. M.; Moreland, J.; Meyers, M. A.; Kohno, T.; Lyons, D.; Lichenstein, H. S. Identification and characterization of a pro-tumor necrosis factor-aprocessing enzyme from the ADAM family of zinc metalloproteases. J. Biol. Chem. 1997, 272, 24588-24593.
40. Lunn, C. A.; Fan, X.; Dalie, B.; Miller, K.; Zavodny, P. J.; Narula, S. K.; Lundell, D. Purification ofADAM10 from bovine spleen as a TNF-a convertase. FEBS Lett. 1997, 400, 333-335.
41. Moss, M.; Becherer, J. D.; Milla, M.; Pahel, G.; Lambert, M.; Andrews, R.; Frye, S.; Haffner, C.; Cowan, D.; Maloney, P. TNF-a convertase. In Metalloproteinases as Targets for Anti-Inflammatory Drugs; Bradshaw, D.; Nixon, J. S.; Bottomley, K., Eds.; Birkhauser: Basel, 1999; pp 87-204.
42. Peschon, J. J.; Slack, J. L.; Reddy, P.; Stocking, K. L.; Sunnarborg, S. W.; Lee, D. C.; Russell, W. E.; Castner, B. J.; Johnson, R. S.; Fitzner, J. N.; Boyce, R.W.; Nelson, N.; Kozlosky, C. J.;Wolfson, M. F.; Rauch, C. T.; Cerretti, D. P.; Paxton, R. J.; March, C. J.; Black, R. A. An essential role for ectodomain shedding in mammalian development. Science. 1998, 282, 1281-1284.
43. Luetteke, N. C.; Qiu, T. H.; Peiffer, R. L.; Oliver, P.; Smithies, O.; Lee, D. C. TGF-a deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell. 1993, 73, 263-278.
44. Mann, G. B.; Fowler, K. J.; Gabriel, A.; Nice, E. C.; Williams, R. L.; Dunn, A. R. Mice with a null mutation of the TGF-a gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell. 1993, 73, 249-261.
45. Miettinen, P. J.; Berger, J. E.; Meneses, J.; Phung, Y.; Pedersen, R. A.;Werb, Z.; Derynck, R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 1995, 376, 337-341.
46. Threadgill, D.W.; Dlugosz, A. A.; Hansen, L. A.; Tennenbaum, T.; Lichti, U.; Yee, D.; LaMantia, C.; Mourton, T.; Herrup, K.; Harris, R. C. et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science. 1995, 269, 230-234.
47. Sibilia, M.; Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 1995, 269, 234-238.
48. Reddy, P.; Slack, J. L.; Davis, R.; Cerretti, D. P.; Kozlosky, C. J.; Blanton, R. A.; Shows, D.; Peschon, J. J.; Black, R. A. Functional analysis of the domain structure of tumor necrosis factor-a converting enzyme. J. Biol. Chem. 2000, 275, 14608-14614.
49. Buxbaum, J. D.; Liu, K. N.; Luo, Y.; Slack, J. L.; Stocking, K. L.; Peschon, J. J.; Johnson, R. S.; Castner, B. J.; Cerretti, D. P.; Black, R. A. Evidence that tumor necrosis factor-a converting enzyme is involved in regulated a-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 1998, 273, 27765-27767.
50. Althoff, K.; Reddy, P.; Voltz, N.; Rose-John, S.; Müllberg, J. Shedding of interleukin-6 receptor and tumor necrosis factor a. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur. J. Biochem. 2000, 267, 2624-2631.
51. Rio, C.; Buxbaum, J. D.; Peschon, J. J.; Corfas, G. Tumor necrosis factor-a-converting enzyme is required for cleavage of erbB4/HER4. J. Biol. Chem. 2000, 275, 10379-10387.
52. Sadhukhan, R.; Santhamma, K. R.; Reddy, P.; Peschon, J. J.; Black, R. A.; Sen, I. Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-a-converting enzyme-deficient mice. J. Biol. Chem. 1999, 274, 10511-10516.
53. Lum, L.;Wong, B. R.; Josien, R.; Becherer, J. D.; Erdjument-Bromage, H.; Schlöndorff, J.; Tempst, P.; Choi, Y.; Blobel, C. P. Evidence for the role of tumour necrosis factor-a (TNF-a)-converting enzyme-like protease in shedding of TRANCE, a TNFfamily member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 1999, 274, 13613-13618.
54. Brou, C.; Logeat, F.; Gupta, N.; Bessia, C.; LeBail, O.; Doedens, J. R.; Cumano, A.; Roux, P.; Black, R. A.; Israël, A. Anovel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell. 2000, 5, 207-216.
55. Solomon, K. A.; Pesti, N.;Wu, G.; Newton, R. C. Cutting edge: a dominant-negative form of TNF-a converting enzyme inhibits proTNF and TNFRII secretion. J. Immunol. 1999, 163, 4105-4108.
56. Schlondorff, J.; Blobel, C. P. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. J. Cell Sci. 1999, 112, 3603-3617.
57. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.;Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature. 1997, 385, 729-732.
58. Schlöndorff, J.; Becherer, J. D.; Blobel, C. P. Intracellular maturation and localization of the tumour necrosis factor-a convertase (TACE). Biochem. J. 2000, 347, 131-138.
59. Doedens, J. R.; Black, R. A. Stimulation-induced downregulation of tumor necrosis factora converting enzyme. J. Biol. Chem. 2000, 275, 14598-14607.
60. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G. P.; Bartunik, H.; Ellestad, G. A.; Reddy, P.;Wolfson, M. F.; Rauch, C. T.; Castner, B. J.; Davis, R.; Clarke, H. R.; Petersen, M.; Fitzner, J. N.; Cerretti, D. P.; March, C. J.; Paxton, R. J.; Black, R. A.; Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-a-converting enzyme. Proc. Natl. Acad. Sci. USA. 1998, 95, 3408-3412.
61. Botos, I.; Scapozza, L.; Zhang, D.; Liotta, L. A.; Meyer, E. F. ;Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc. Natl. Acad. Sci. USA. 1996, 93, 2749-2754.
62. Cirilli, M.; Gallina, C.; Gavuzzo, E.; Giordano, C.; Gomis-Rüth, F. X.; Gorini, B.; Kress, L. F.; Mazza, F.; Paradisi, M. P.; Pochetti, G.; Politi,V. 2Å X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode. FEBS Lett. 1997, 418, 319-322.
63. Gomis-Rüth, F. X.; Meyer, E. F.; Kress, L. F.; Politi, V. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor-a convertase inhibitors. Protein Sci. 1998, 7, 283-292.
64. Gonnella, N. C.; Li, Y. C.; Zhang, X.; Paris, C. G. Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg. Med. Chem. 1997, 5, 2193-2201.
65. Roghani, M.; Becherer, J. D.; Moss, M. L.; Atherton, R. E.; Erdjument-Bromage, H.; Arribas, J.; Blackburn, R. K.; Weskamp, G.; Tempst, P.; Blobel, C. P. Metalloproteasedisintegrin MDC9: intracellular maturation and catalytic activity. J. Biol. Chem. 1999, 274, 3531-3540.
66. Parker,D. T.; O'Byrne, E.; Goldemberg, R.; Ganu, V.; Melton, R.; Blancuzzi, V.;Wilson, D.; Hu, S.-I.; Roberts, E. D.; Singh, H.; Ludewing, R.; MacPerson, L. J. The development of 27023A: a novel, potent, and orally active matrix metalloprotease inhibitor. Fourth International Conference, Inflammation Research Association, White Haven, PA, USA, 1994, p 73 (abstracts).
67. Barberia, J. T.; Carty, T. J.; Georghean, K. F. Development of a cell-based assay for TNF-a release which avoids transcription and translation steps. Fifth International Conference, Inflammation Research Association, Hershey, PA, USA, 1996, p 1 (abstracts).
68. Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. TACE andADAMproteases as target for drug discovery. Drug Discov. Today. 2001, 6, 417-426.
69. Barlaam, B.; Bird, T. G.; Lambert-Van Der Brempt, C.; Campbell, D.; Foster, S. J.; Maciewicz, R. New a-substituted succinate-based hydroxamic acids as TNF-a convertase inhibitors. J. Med. Chem. 1999, 42, 4890-4908.
70. Andrews, R. C.; Anderson, M.W.; Stanford, J. B.; Bubacz, D. G.; Chan, J. H.; Cowan, D. J.; Gaul, M. D.; McDougald, D. L.; Musso, D. L.; Rabinowitz, M. H.;Wiethe, R.W. Brit. UK Pat. Appl. GB 2348198, 2000.
71. Rabinowitz, M. Synthesis and evaluation of novel N-hydroxy formamide inhibitors of tumor necrosis factor-a converting enzyme. 220th National Meeting of the American Chemical Society, Washington, DC; American Chemical Society, Washington, DC, 2000.
72. Broadhurst, M. J.; Johnson, W. H.; Walter, D. S. Cyclic hydrazine derivatives as TNF-a inhibitors.PCT Int. Appl. WO 0035885 A1, 2000.
73. Nixon, J. S.; Bottomley, K. M. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Exp. Opin. Invest. Drugs. 2000, 9, 1469-1478.
74. McClure, K. F.; Noe, M. C.; Letavic, M. A.; Chupak, L. S. Preparation of 4-phenylsulfonyl-3-morpholinehydroxamic acids and analogs as tumor necrosis factor-a-convertase inhibitors. PCT Int. Appl. WO 0009492 A1, 2000.
75. Levin, J. I.; Du Mila, T.; Venkatesan, A. M.; Nelson, F. C.; Zask, A.; Gu, Y. The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors. PCT Int. Appl.WO9816503, 1998.
76. Levin, J. I.; Du, M. T.; DiJoseph, J. F.; Killar, L. M.; Sung, A.;Walter, T.; Sharr, M. A.; Roth, C. E.; Moy, F. J.; Powers, R.; Jin, G.; Cowling, R.; Skotnicki, J. S. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg. Med. Chem. Lett. 2001, 11, 235-238.
77. Xue, C.-B.; Chemey, R. J.; Decicco, C. P.; DeGrado, W. F.; He, X.; Hodge, C. N.; Jacobson, I. C.; Magolda, R. L.; Arner, E. C.; Duma, J.; Nelson, D. J. Patent Appl. WO9718207, 1997.
78. Xue, C. B.; He, X.; Roderick, J.; Corbett, R. L.; Duan, J. J.; Liu, R. Q.; Covington, M. B.; Newton, R. C.; Trzaskos, J. M.; Magolda, R. L.;Wexler, R. R.; Decicco, C. P. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-a converting enzyme inhibitors. Part 1: lead Identification. Bioorg. Med Chem. Lett. 2003, 13, 4293-4297.
79. Xue, C. B.; He, X.; Roderick, J.; Corbett, R. L.; Duan, J. J.; Liu, R. Q.; Covington, M. B.; Qian, M.; Ribadeneira, M. D.;Vaddi, K.; Christ, D. D.; Newton, R. C.; Trzaskos, J. M.; Magolda, R. L.;Wexler, R. R.; Decicco, C. P. Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-a converting enzyme inhibitors. Part 2: lead Optimization. Bioorg. Med. Chem. Lett. 2003, 13, 4299-4304.
80. Duan, J. J.; Lu, Z.; Xue, C. B.; He, X.; Seng, J. L.; Roderick, J. J.;Wasserman, Z. R.; Liu, R. Q.; Covington, M. B.; Magolda, R. L.; Newton, R. C.; Trzaskos, J. M.; Decicco, C. P. Discovery of N-Hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. 2003, 13, 2035-2040.
81. Duan, J. J.; Chen, L.;Wasserman, Z. R.; Lu, Z.; Liu, R. Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D. D.;Wexler, R. R.; Decicco, C. P. Discovery of g-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor a converting enzyme: design, synthesis, and structure-activity relationships. J. Med. Chem. 2002, 45, 4954-4957.
82. Gilmore, J. L.; King, B. W.; Harris, C.; Maduskuie, T.; Mercer, S. E.; Liu, R. Q.; Covington, M. B.; Qian, M.; Ribadeneria, M. D.; Vaddi, K.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P.; Duan, J. J. Synthesis and structure-activity relationship of a novel, achiral series of TNF-a converting enzyme inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2699-2704.
83. Duan, J. J.; Chen, L.; Lu, Z.; Xue, C. B.; Liu, R. Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.;Vaddi, K.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. Discovery of b-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 241-247.
84. Ott, G. R.; Asakawa, N.; Lu, Z.; Liu, R. Q.; Covington, M. B.; Vaddi, K.; Qian, M.; Newton, R. C.; Christ, D. D.; Traskos, J. M.; Decicco, C. P.; Duan, J. J. a,b-Cyclic-bbenzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). Bioorg. Med. Chem. Lett. 2008, 18, 694-699.
85. Ott, G. R.; Asakawa, N.; Lu, Z.; Anand, R.; Liu, R. Q.; Covington, M. B.; Vaddi, K.; Qian, M.; Newton, R. C.; Christ, D. D.; Trzaskos, J. M.; Duan, J. J. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-a converting enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P10 substituents. Bioorg. Med. Chem. Lett. 2008, 18, 1577-1582.
86. Sawa, M.; Kiyoi, T.; Kurokawa, K.; Kumihara, H.;Yamamoto, M.; Miyasaka, T.; Ito, Y.; Hirayama, R.; Inoue, T.; Kirii, Y.; Nishiwaki, E.; Ohmoto, H.; Maeda, Y.; Ishibushi, E.; Inoue, Y.; Yoshino, K.; Kondo, H. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids. J. Med. Chem. 2002, 45, 919-929.
87. Sawa, M.; Kiyoi, T.; Kurokawa, K.; Kumihara, H.;Yamamoto, M.; Miyasaka, T.; Ito, Y.; Hirayama, R.; Inoue, T.; Kirii, Y.; Nishiwaki, E.; Ohmoto, H.; Maeda, Y.; Ishibushi, E.; Inoue, Y.;Yoshino, K.;Kondo, H. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. 2003, 13, 2021-2024.
88. Sawa, M.; Kondo, H.; Nishimura, S. Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom. Bioorg. Med. Chem. Lett. 2002, 12, 581-584.
89. Levin, J. I.; Chen, J. M.; Cheung, K.; Cole, D.; Crago, C.; Santos, E. D.; Du, X.; Khafizova, G.; MacEwan, G.; Niu, C.; Salaski, E. J.; Zask, A.; Cummons, T.; Sung, A.; Xu, J.; Zhang, Y.; Xu, W.; Ayral-Kaloustian, S.; Jin, G.; Cowling, R.; Barone, D.; Mohler, K. M.; Black, R. A.; Skotnicki, J. S. Acetylenic TACE inhibitors. Part 1: SAR of the acyclic sulfonamide hydroxamates. Bioorg. Med Chem. Lett. 2003, 13, 2799-2803.
90. Zhang,Y.; Hegen, M.; Xu, J.;Keith, J. C., Jr.; Jin, G.; Du, X.; Cummons, T.; Sheppard, B. J.; Sun, L.; Zhu, Y.; Rao, V. R.;Wang, Q.; Xu, W.; Cowling, R.; Nickerson-Nutter, C. L.; Gibbons, J.; Skotnicki, J.; Lin, L. L.; Levin, J. Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-a converting enzyme. Int. Immunopharmacol. 2004, 4, 1845-1857.
91. Zhang, Y.; Xu, J.; Levin, J.; Hegen, M.; Li, G.; Robertshaw, H.; Brennan, F.; Cummons, T.; Clarke, D.; Vansell, N.; Nickerson-Nutter, C.; Barone, D.; Mohler, K.; Black, R.; Skotnicki, J.; Gibbons, J.; Feldmann, M.; Frost, P.; Larsen, G.; Lin, L. L. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmcol. Exp. Ther. 2004, 309, 348-355.
92. Levin, J. I.; Chen, J. M.; Laakso, L. M.; Du, M.; Du, X.;Venkatesan, A. M.; Sandanayaka, V.; Zask, A.; Xu, J.; Xu, W.; Zhang, Y.; Skotnicki, J. S. Acetylenic TACE inhibitors. Part 2: SAR of sixmembered cyclic sulfonamide hydroxamates. Bioorg. Med. Chem. Lett. 2005, 15, 4345-4349.
93. Levin, J. I.; Chen, J. M.; Laakso, L. M.; Du, M.; Schmid, J.; Xu, W.; Cummons, T.; Xu, J.; Jin, G.; Barone, D.; Skotnicki, J. S. Acetylenic TACE inhibitors. Part 3: thiomorpholine sulfonamide hydroxamates. Bioorg. Med. Chem. Lett. 2006, 16, 1605-1609.
94. Venkatesan, A. M.; Davis, J. M.; Grosu, G. T.; Baker, J.; Zask, A.; Levin, J. I.; Ellingboe, J.; Skotnicki, J. S.; Dijoseph, J. F.; Sung, A.; Jin, G.; Xu, W.;McCarthy, D. J.; Barone, D. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors. J. Med. Chem. 2004, 47, 6255-6269.
95. Kaapjoo Park, K.; Aplasca, A.; Du, M. T.; Sun, L.; Zhu, Y.; Zhang, Y.; Levin, J. I. Design and synthesis of butynyloxyphenyl b-sulfone piperidine hydroxamates as TACE inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3927-3931.
96. Condon, J. S.; Joseph-McCarthy, D.; Levin, J. I.; Lombart, H. G.; Lovering, F. E.; Sun, L.; Wang, W.; Xu, W.; Zhang,Y. Identification of potent and selective TACE inhibitors via the S1 pocket. Bioorg. Med. Chem. Lett. 2007, 17, 34-39.
97. Zhu, Z.; Mazzola, R.; Sinning, L.; McKittrick, B.; Niu, X.; Lundell, D.; Sun, J.; Orth, P.; Guo, Z.; Madison, V.; Ingram, R.; Beyer, B. M. Discovery of novel hydroxamates as highly potent tumor necrosis factor-a converting enzyme inhibitors. Part I: discovery of two binding modes. J. Med. Chem. 2008, 51, 725-736.
98. Lukacova,V.; Zhang, Y.; Kroll, D. M.; Raha, S.; Comez, D.; Balaz, S. Acomparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. J. Med. Chem. 2005, 48, 2361-2370.
99. Duan, J. J.; Chen, L.; Lu, Z.; Jiang, B.; Asakawa, N.; Sheppeck, J. E., 2nd; Liu R. Q.; Covington, M. B.; Pitts, W.; Kim, S. H.; Decicco, C. P. Discovery of low nanomolar nonhydroxamate inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. 2007, 17, 266-271.
100. Sheppeck, J. E., 2nd; Tebben A.; Gilmore, J. L.;Yang, A.;Wasserman, Z. R.; Decicco, C. P.; Duan, J. J. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. Bioorg. Med. Chem. Lett. 2007, 17, 1408-1412.
101. Sheppeck, J. E., 2nd; Gilmore J. L.; Tebben, A.; Xue, C. B.; Liu, R. Q.; Decicco, C. P.; Duan, J. J. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-a converting enzyme (TACE). Bioorg. Med. Chem. Lett. 2007, 17, 2769-2774.
102. Brandstetter, H.; Grams, F.; Glitz, D.; Lang, A.; Huber, R.; Bode, W.; Krell, H.W.; Engh, R. A. The 1.8-Å crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition. J. Biol. Chem. 2001, 276, 17405-17412.
103. Bandarage, U. K.;Wang, T.; Come, J. H.; Perola, E.;Wei, Y.; Rao, B. G. Novel thiol-based TACE inhibitors. Part 2: rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg. Med. Chem. Lett. 2008, 18, 44-48.
104. Gonzales, P. E.; Solomon, A.; Miller, A. B.; Leesnitzer, M. A.; Sagi, I.; Milla, M. E. Inhibition of the tumor necrosis factor-a-converting enzyme by its pro domain. J. Biol. Chem. 2004, 279, 31638-31645.
105. Milla, M. E.; Leesnitzer, M. A.; Moss, M. L.; Clay, W. C.; Carter, H. L.; Miller, A. B.; Su, J. L.; Lambert, M. H.; Willard, D. H.; Sheeley, D. M.; Kost, T. A.; Burkhar, W.; Moyer, M.; Blackburn, R. K.; Pahel, G. L.; Mitchell, J. L.; Hoffman, C. R.; Becherer, J. D. Specific sequence elements are required for the expression of functional tumor necrosis factor-a-converting enzyme (TACE). J. Biol. Chem. 1999, 274, 30563-31645.
106. Moss, M. L.; Bomar, M.; Liu, Q.; Sage, H.; Dempsey, P.; Lenhart, P. M.; Gillispie, P. A.; Stoeck, A.; Wildeboer, D.; Bartsch, J. W.; Palmisano, R.; Zhou, P. The ADAM10 prodomain is a specific inhibitor of ADAM-10 proteolytic activity and inhibits cellular shedding events. J. Biol. Chem. 2007, 282, 35712-35721.
107. Mass, R. D. The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 932-940.
108. Carney,W. P.; Neumann, R.; Lipton, A.; Leitzel, K.; Ali, S.; Price, C. P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 2003, 49, 1579-1598.
109. Arribas, J.; Borroto, A. Protein ectodomain shedding. Chem. Rev. 2002, 102, 4627-4637.
110. Marmor,M. D.; Skaria, K. B.; Yarden, Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 903-913.
111. Molina,M.A.; Saez, R.; Ramsey, E. E.;Garcia-Barchino, M.-J.;Rojo, F.; Evans, A. J.; Albanell, J.; Keenan, E. J.; Lluch, A.; Garcia-Conde, J.; Baselga, J.; Clinton, G. M. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 2002, 8, 347-353.
112. Banner, L. C.; Co, E.W.; Jammalamadaka, V.; Nuss, J. M.; Kim, M. H.; Le, D. T.; Lew, A.; Mac Morrison, B.; Mamo, S.; Wen, Z.; Xu, W. Human ADAM-10 Inhibitors. WO 03106381, 2003.
113. Yao,W.; Zhuo, J.; Burns, D. M.; Li, Y. L.; Qian, D. Q.; Zhang, C.; He, C.; Xu, M.; Shi, E.; Li, Y.; Marando, C. A.; Covington, M. B.;Yang, G.; Liu, X.; Pan, M.; Fridman, J. S.; Scherle, P.; Wasserman, Z. R.; Hollis, G.; Vaddi, K.; Yeleswaram, S.; Newton, R.; Friedman, S.; Metcalf, B. Design and identification of selective HER-2 sheddase inhibitors via P10 manipulation and unconventional P20 perturbations to induce a molecular metamorphosis. Bioorg. Med. Chem. Lett. 2008, 18, 159-163.
114. Liu, X.; Fridman, J. S.; Wang, Q.; Caulder, E.; Yang, G.; Covington, M.; Liu, C.; Marando, C.; Zhuo, J.; Li, Y.; Yao, W.; Vaddi, K.; Newton, R. C.; Scherle, P. A.; Friedman, S. M. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol. Ther. 2006, 5, 648-656.
115. Zhou, B. B.; Peyton, M.; He, B.; Liu, C.; Girard, L.; Caudler, E.; Lo, Y.; Baribaud, F.; Mikami, I.; Reguart, N.; Yang, G.; Li, Y.; Yao, W.; Vaddi, K.; Gazdar, A. F.; Friedman, S. M.; Jablons, D. M.; Newton, R. C.; Fridman, J. S.; Minna, J. D.; Scherle, D. A. TargetingADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in nonsmall cell lung cancer. Cancer Cell. 2006, 10, 39-50.
116. Yao, W.; Zhuo, J.; Burns, D. M.; Xu, M.; Zhang, C.; Li, Y. L.; Qian, D. Q.; He, C.; Weng, L.; Shi, E.; Lin, Q.; Agrios, C.; Burn, T. C.; Caulder, E.; Covington, M. B.; Fridman, J. S.; Friedman, S.; Katiyar, K.; Hollis, G.; Li, Y.; Liu, C.; LiuX.; Marando, C. A.; Newton, R.; Pan, M.; Scherle, P.; Taylor, N.; Vaddi, K.;Wasserman, Z. R.; Wynn, R.; Yeleswaram, S.; Jalluri, R.; Bower, M.; Zhou, B. B.; Metcalf, B. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. J. Med. Chem. 2007, 50, 603-606.
117. Infante, J.; Burris, H. A.; Lewis, N.; Donehower, R.; Redman, J.; Friedman, S.; Scherle, P.; Fridman, J.; Li, J.; Emm, T.; Troy, S.; Eckhardt, S. G. 30th San Antonio Breast Cancer Symposium; Poster No. 6064; 2007 December 13-16, San Antonio, TX,USA,www.incyte.com.
118. Witters, L.; Scherle, P.; Friedman, S.; Fridman, J.; Caulder, E.; Newton, R.; Lipton, A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008, 68, 7083-7089.
119. Wenquing, Y.; Zhou, J.; Xu, M.; Zhang, F.; Metcalf, B. Aza spiro alcane derivatives as inhibitors of metalloproteinases. PCT WO 04096139, 2004.
120. Burns, D. M.; He, C.; Li, Y.; Scherle, P.; Liu, X.; Marando, C. A.; Covington, M. B.; Yang, G.; Pan, M.; Turner, S.; Fridman, J. S.; Hollis, G.; Vaddi, K.; Yeleswaram, S.; Newton, R.; Friedman, S.; Metcalf, B.; Yao,W. Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P01 permutations. Bioorg. Med. Chem. Lett. 2008, 18, 560-564.
121. Li, Y.-L.; Zhou, J.; Burns, D.; Yao, W. A preparation of (hetero)cyclic N-hydroxycarboxamide derivatives, useful as inhibitors of matrix metalloproteinases (MMPs). PCT WO 05037826, 2005.
122. Schaub, M. C.; Hefti, M. A.; Zuellig, R.A.; Morano, I. Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc. Res. 1998, 37, 381-404.
123. Elliott, P.; McKenna, W. J. Hypertrophic cardiomyopathy. Lancet. 2004, 363, 1881-1891.
124. Asakura, M.; Kitakaze, M.; Takashima, S.; Liao, Y.; Ishikura, F.; Yoshinaka, T.; Ohmoto, H.; Node, K.;Yoshino, K.; Ishiguro, H.; Asanuma, H.; Sanada, S.; Matsumura, Y.; Takeda, H.; Beppu, S.; Tada, M.; Hori, M.; Higashiyama, S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8, 35-40.
125. Grüneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J. Med. Chem. 2002, 45, 3588-3602.
126. Oh, M.; Im, I.; Lee, Y. J.; Kim, Y. H.;Yoon, J. H.; Park, H. G.; Higashiyama, S.; Kim, Y. C.; Park,W. J. Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 6071-6074.
127. Jones, G. C. ADAMTS Proteinases: potential therapeutic targets? Curr. Pharm. Biotechnol. 2006, 7, 25-31.
128. Takizawa, M.; Yatabe, T.; Okada, A.; Chijiiwa, M.; Ghosh, P.; Okada, Y. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett. 2008, 582, 2945-2949.
129. Okada, Y. Proteinases and matrix degradation. In Kelley's Textbook of Rheumatology, Firestein, G. S.; Budd, R. C.; Harris, E. D., Jr.; McInnes, I. B. Ruddy, S., Sergent, J. S. 8th ed.; Elsevier Saunders: Philadelphia.
130. Porter, S.; Clark, I. M.;Kevorkian, L.; Edwards, D. R. TheADAMTSmetalloproteinases. Biochem. J. 2005, 386, 15-27.
131. Fosang, A. J.; Neame, P. J.; Last, K.; Hardhingham, T. E.; Murphy, G.; Hamilton, J. A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem. 1992, 267, 19470-19474.
132. Flannery, C. R.; Lark, M. W.; Sandy, J. D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J. Biol. Chem. 1992, 267, 1008-1014.
133. Fosang, A. J.; Last, K.; Knauper, V.; Neame, P. J.; Murphy, G.; Hardingham, T. E.; Tschesche, H.; Hamilton, J. A. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem. J. 1993, 295, 273-276.
134. Fosang, A. J.; Last, K.; Knauper, V.; Murphy, G.; Neame, P. J. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996, 380, 17-20.
135. Tortorella, M. D.; Burn, T. C.; Pratta, M. A.; Abbaszade, I.; Hollis, J. M.; Liu, R.; Rosenfeld, S. A.; Copeland, R. A.; Decicco, C. P.;Wynn, R.; Rockwell, A.; Yang, F.; Duke, J. L.; Solomon, K.; George, H.; Bruckner, R.; Nagase, H.; Itoh, Y.; Ellis, D. M.; Ross, H.;Wiswall, B. H.; Murphy, K.; Hillman, M. C., Jr.; Hollis, G. F.; Newton, R. C.; Magolda, R. L.; Trzaskos, J. M.; Arner, E.C. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999, 284, 1664-1666.
136. Arner, E. C.; Hughes, C. E.; Decicco, C. P.; Caterson, B.; Tortorella, M. D. Cytokineinduced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage. 1998, 6, 214-228.
137. Arner, E. C.; Pratta, M. A.; Trzaskos, J. M.; Decicco, C. P.; Tortorella, M. D. Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J. Biol. Chem. 1999, 274, 6594-6601.
138. Glasson, S. S.; Askew, R.; Sheppard, B.; Carito, B.; Blanchet, T.; Ma, H. L.; Flannery, C. R.; Peluso, D.; Kanki, K.; Yang, Z.; Majumdar, M. K.; Morris, E. A. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005, 434, 644-648.
139. Stanton, H.; Rogerson, F. M.; East, C. J.; Golub, S. B.; Lawlor, K. E.; Meeker, C. T.; Little, C. B.; Last, K.; Farmer, P. J.; Campbell, I. K.; Fourie, A. M.; Fosang, A. J. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005, 434, 648-652.
140. Bau, B.; Gebhard, P. M.; Haag, J.; Knorr, T.; Bartnik, E.; Aigner, T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002, 46, 2648-2657.
141. Moulharat, N.; Lesur, C.; Thomas, M.; Rolland-Valognes, G.; Pastoureau, P.; Anract, P.; De Ceuninck, F.; Sabatini, M. Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthritis Cartilage. 2004, 12, 296-305.
142. Hui, W.; Barksby, H. E.; Young, D. A.; Cawston, T. E.; McKie, N.; Rowan, A. D. Oncostatin M in combination with tumour necrosis factor alpha induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or-2. Ann. Rheum. Dis. 2005, 64, 1624-1632.
143. Gerhardt, S.; Hassall, G.; Hawtin, P.; McCall, E.; Flavell, L.; Minshull, C.; Hargreaves, D.; Ting, A.; Pauptit, R. A.; Parker, A. E.; Abbott, W. M. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J. Mol. Biol. 2007, 373, 891-902.
144. Mosyak, L.; Georgiadis, K.; Shane, T.; Svenson, K.; Hebert, T.; McDonagh, T.; Mackie, S.; Olland, S.; Lin, L.; Zhong, X.; Kriz, R.; Reifenberg, E. L.; Collins-Racie, L. A.; Corcoran, C.; Freeman, B.; Zollner, R.; Marvell, T.; Vera, M.; Sum, P. E.; Lavallie, E. R.; Stahl, M.; Somers, W. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci. 2008, 17, 16-21.
145. Shieh, H. S.; Mathis, K. J.; Williams, J. M.; Hills, R. L.; Wiese, J. F.; Benson, T. E.; Kiefer, J. R.; Marino, M. H.; Carroll, J. N.; Leone, J.W.; Malfait, A. M.; Arner, E. C.; Tortorella, M. D.; Tomasselli, A. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J. Biol. Chem. 2008, 283, 1501-1507.
146. Yao,W.;Wasserman, Z. R.; Chao, M.; Reddy, G.; Shi, E.; Liu, R. Q.; Covington, M. B.; Arner, E. C.; Pratta, M. A.; Tortorella, M.; Magolda, R. L.; Newton, R.; Qian, M. X.; Ribadeneira, M. D.; Christ, D.;Wexler, R. R.; Decicco, C. P. Design and synthesis of a series of (2R)-N4-Hydroxy-2-(3-hydroxybenzyl)-N1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J. Med. Chem. 2001, 44, 3347-3350.
147. Cherney, R. J.; Mo, R.; Meyer, D. T.; Wang, L.; Yao, W.; Wasserman, Z. R.; Liu, R. Q.; Covington, M. B.; Tortorella, M. D.; Arner, E. C.; Qian, M.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Magolda, R. L.; Decicco, C. P. Bioorg. Med. Chem. Lett. 2003, 13, 1297.
148. Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow, L. L.; Yocum, S. A.; Rosner, P. J.; Geoghegan, K. F.; Hambor, J. E. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Invest. 1996, 97, 761-768.
149. Noe, M. C.; Snow, S. L.; Wolf-Gouveia, L. A.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Liras, J. L.; Vaughn, M. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase. Bioorg. Med. Chem. Lett. 2004, 14, 4727-4730.
150. Noe, M. C.; Natarajan, V.; Snow, S. L.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Carty, T. J.; Barberia, J. A.; Sweeney, F. J.; Liras, J. L.; Vaughn, M.; Hardink, J. R.; Hawkins, J. M.; Tokar, C. Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 2005, 15, 2808-2811.
151. Noe, M. C.; Natarajan, V.; Snow, S. L.;Wolf-Gouveia, L. A.; Mitchell, P. G.; Lopresti-Morrow, L.; Reeves, L. M.; Yocum, S. A.; Otterness, I.; Bliven, M. A.; Carty, T. J.; Barberia, J. T.; Sweeney, F. J.; Liras, J. L.; Vaughn, M. Discovery of 3-OH-3-methylpipecolic hydroxamates: Potent orally active inhibitors of aggrecanase and MMP-13. Bioorg. Med. Chem. Lett. 2005, 15, 3385-3388.
152. Xiang, J. S.; Hu, Y.; Rush, T. S.; Thomason, J. R.; Ipek, M.; Sum, P.-E.; Abrous, L.; Sabatini, J. J.; Georgiadis, K.; Reifenberg, E.; Majumdar, M.; Morrisc, E. A.; Tam, S. Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 311-316.
153. Inaba,T.;Haas, J.;Shiozaki, M.;Litman, N.M.;Yasue, K.;Andrews, S.W.;Sakai, A.;Fryer, A.M.; Matsuo, T.; Laird, E. R.; Suma, A.; Shinozaki, Y.; Hori, Y.; Imai, H.; Negoro, T. Cyclopropane compounds and pharmaceutical use thereof. PCT WO 058884, 2005.
154. Gallagher, B. M.;VanVeldhuizen, J.; Deng, H.; Sucholeiki, I.; Hochguertel, M.; Bluhm, H.; Taveras, A. G. Heterobicyclic metalloproteinase inhibitors. PCT/US 2007/0155737.
155. Engel, C. K.; Pirard, B.; Schimanski, S.; Kirsch, R.; Habermann, J.; Klinger, O.; Schlotte, V.; Weithmann, K. U.; Wendt, U. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 2005, 12, 181-189.
156. Takizawaa,M.;Yatabea, T.;Okadaa, A.;Chijiiwaa, M.;Mochizukia, S.;Ghoshb, P.;Okada, Y. Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes. FEBS Lett. 2008, 582, 2945-2949.
157. Cullis-Hill, D. Treatment of osteoporosis. PCT WO 02/41901, 2002.
158. Bursavich, M. G.; Gilbert, A. M.; Lombardi, S.; Georgiadis, K. E.; Reifenberg, E.; Flannery, C. R.; Morris, E. A. Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg. Med. Chem. Lett. 2007, 17, 1185-1188.
159. Gilbert, A. M.; Bursavich, M. G.; Lombardi, S.; Georgiadis, K. E.; Reifenberg, E.; Flannery, C. R.; Morris, E. A. 5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorg. Med. Chem. Lett. 2007, 17, 1189-1192.
160. Gilbert, A. M.; Bursavich, M. G.; Lombardi, S.; Georgiadis, K. E.; Reifenberg, E.; Flannery, C. R.; Morris, E. A. 50-Phenyl-30H-spiro[indoline-3,20-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg. Med. Chem. Lett. 2007, 17, 5630-5633.
161. Bursavich, M. G.; Lombardi, S.; Gilbert, A. M. PCT/US2007/013530.
162. Sum, P.-E.; How, D. B.; Sabatini, J. J.; Xiang, J. S.; Ipek, M.; Feyfant, E.PCT/US2006/027066.